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Abstract: Resveratrol, because of its low solubility in water and its high membrane permeability,
is collocated in the second class of the biopharmaceutical classification system, with limited
bioavailability due to its dissolution rate. Solid dispersion of resveratrol supported on Magnesium
DiHydroxide (Resv@MDH) was evaluated to improve solubility and increase bioavailability of
resveratrol. Fluorimetric microscopy analysis displays three types of microparticles with similar
size: Type 1 that emitted preferably fluorescence at 445 nm with bandwidth of 50 nm, type 2 that
emitted preferably fluorescence at 605 nm with bandwidth of 70 nm and type 3 that is non-fluorescent.
Micronized pure resveratrol displays only microparticles type 1 whereas type 3 are associated to
pure magnesium dihydroxide. Dissolution test in simulated gastric environment resveratrol derived
from Resv@MDH in comparison to resveratrol alone displayed better solubility. A 3-fold increase of
resveratrol bioavailability was observed after oral administration of 50 mg/kg of resveratrol from
Resv@MDH in rabbits. We hypothesize that type 2 microparticles represent magnesium dihydroxide
microparticles with a resveratrol shell and that they are responsible for the improved resveratrol
solubility and bioavailability of Resv@MDH.
Keywords: resveratrol; magnesium dihydroxide; solubility; bioavailability; dissolution rate;
microparticles
1. Introduction
Resveratrol (trans-3,5,4′-tri-hydroxic-stilbene) is a stilbenic structure polyphenol, initially isolated
from the root of the white hellebore (Veratrum Grandiflorum O. Loes) and later from the root of the
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Polygonum cuspidatum, a plant used in traditional Chinese and Japanese medicine. Resveratrol
became popular in 1992 when it was suggested that it could be the reason behind red wine’s
cardio-protective effects (French paradox; [1]), and its popularity increased in 1997 when it was
proven that resveratrol was able to prevent colorectal cancer in mice [1]. Resveratrol based compounds
present anti-oxidant, anti-inflammatory, anti-viral, cardio-protective, neuro-protective, anti-cancer and
anti-angiogenetic activities [1–3]. It has been recently observed in obese human subjects that treatment
with trans-resveratrol reduces glucose, triglycerides and inflammatory marker levels with a similar
effect to the one induced by caloric restriction [4]. The mechanism of action of resveratrol has not
been completely defined yet, and for this reason recently studies have been carried out in order to
understand the aspects that are still not clear [4].
Resveratrol is poorly bioavailable because of reduced absorption mainly due to its low solubility
and fast metabolism that converts it into glucuronide and sulfates compounds [1,5]. In humans
resveratrol can be detected in plasma about 30 min after oral administration, meaning that its
absorption already starts at the gastric level and reaches a plasmatic submicromolar concentration peak.
Such peak is variable and hardly related to the used dose. For example, by administrating a 25 mg dose
of resveratrol a 10 ng/mL plasmatic concentration is obtained, while increasing such dose by 20 times
(500 mg/day) its plasma level increases only seven times (72.6 ng/mL) [6]. Differences in resveratrol
absorption have been demonstrated by clinical trials based on the oral administration of 150 mg/day
of resveratrol for a prolonged period of time. It has been observed that the same dose produces
different plasmatic concentrations: 231 ng/mL [4] and 24.8 ng/mL [7]. Several strategies have been
performed to increase its bioavailability and improve its potential health properties. A recent revision
of the literature highlights how the increased bioavailability of resveratrol is a necessary element in
order to evaluate the real pharmaceutical and health potential of this well-known polyphenol [5].
According to the biopharmaceutical classification system (BCS) [8,9], resveratrol belongs to the second
class which means that it is characterized by low solubility in water (about 30 mg/L), while it shares
a high membrane permeability (log P~3.1) [10]. Among the different strategies, new formulations
have been developed that are able to increase its apparent solubility for example by using a lipophilic
vehicle or through various processes such as the complexation with cyclodextrins, nanopreparation,
or micellar solubilization with biliary acid [10–12]. It has been demonstrated, in in vitro studies,
that the increase of apparent resveratrol solubility allows a partial saturation of the mechanisms that are
involved in its metabolism (conjugation) with a subsequent increase of resveratrol’s bioavailability [13].
This is in accordance with BCS for molecules class II that increasing resveratrol apparent solubility
produces a bioavailability improvement [8,9,14], but in a dedicated study the increased solubility with
cyclodextrins doesn’t modify its bioavailability [12].
In the present study we investigated that the solid dispersion of resveratrol on magnesium
dihydroxide increases its solubility and bioavailability indicating that in some instance this approach
could be exploited to enhance biological properties of resveratrol. Although resveratrol does not
display chelating properties, some studies have shown its ability to interact with heavy metals such as
copper, zinc and aluminum [15,16]. In this work we report that resveratrol interacts with magnesium
dihydroxide at the microparticle level and that this is able to modify its bioavailability.
2. Material and Methods
2.1. Solid Dispersion of Resveratrol on Magnesium Dihydroxide Preparation
Magnesium dihydroxide and resveratrol (from Polygomun cuspidatum, 98% pure) solid dispersion
was performed by modified co-precipitation method of Biswicka et al. [17]. Magnesium dihydroxide
on resveratrol solid dispersion and pure micronized resveratrol described in this study was obtained
by Good Manufacturing Practice (GMP) chain by Prolabin & Tefarm, Ponte Felcino (PG) and
distributed by S&R Farmaceutici SpA, Via dei Pioppi 2, 06083 Bastia Umbra (PG), with the trade
name, Revifast®(produced by the manufacturer La Sorgente del Benessere, Via Prenestina, 141 -02014
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Fiuggi (FR) Italy on behalf of S&R Farmaceutici S.p.A) The resveratrol content in the solid dispersion
was evaluated using the HPLC method (see below). The mean value obtained in the three samples
was about 30% and 70% of total weight of resveratrol and magnesium dihydroxide, respectively.
2.2. Particle Size Analysis
The size of the particles was determined using a Malvern Mastersizer 2000, a laser diffraction
particle size analyzer, for the dried powders.
2.3. Dissolution Assays
A weighed amount of RSV@MDH or resveratrol were placed in series of closed flat-bottomed
glass vessels containing 250 mL of Simulated Gastric Fluid (SGF). The composition of SGF was 35 mM
of NaCl, pH 1.2 with HCl. The vessels were inserted in shaking water bath (Nuve ST 30) at 37 ◦C
and 110 rpm for 2 h. At appropriate times (1, 3, 5, 10, 15, 20, 30, 45, 60, 90 and 120 min) 2 mL
samples were withdrawn and replaced by fresh dissolution medium, then filtered (Spartan 13/02 RC,
Whatman GmbH, Dassel, Germany) and analyzed. The drug concentration was determined by HPLC
(see below).
2.4. Field Emission Scanning Electron Microscopy
The morphology of the samples was investigated with a FEG LEO 1525 scanning electron
microscope (FE-SEM). FE-SEM micrographs were collected by depositing the samples on a stub
holder and after sputter coating with chromium for 20 s.
2.5. Fluorescence Microscopy
Microscopic fluorescence analysis of powders was performed using an Axio Esaminer (Zeiss,
Jena, Germany) fluorescence microscope with a CCD digital camera Axio Cam 502 Mono. Samples
have been observed with DAPI filter (G 365, FT 395, BP 445/50), and with Rhodamine (BP 545/25,
FT 570, BP 605/70) using for excitation mercury lamp (HXP 120V). Image acquisition and analysis was
performed with Zen 2 software (Zeiss, Jena, Germany).
2.6. In Vivo Absorption Test
The trial was carried out at the experimental farm of the University of Batumi, Georgia. Rabbits
were exposed to a continuous photoperiod of 16 h light per day at 40 lx. Room temperature ranged
from 18 to 27 ◦C. Fresh water was always available. Animals were fed with 130 g/day of a standard diet.
The experimental protocol was approved by the Local Ethical Committee for Animal Experimentation
at the University Batumi, Georgia. All efforts were made to minimize animal distress and to use only
the number of animals necessary to produce reliable results. The tests were conducted on New Zealand
White hybrid rabbits (4.5–5 kg weight range). Two groups of four animals each were prepared for the
comparative treatment of resveratrol (pure resveratrol versus Resv@MDH). The rabbits were fasted for
24 h before administration of a suspension containing 50 mg/kg of pure resveratrol or 50 mg/kg of
resveratrol from Resv@MDH according to Jaisamut et al., 2017 [18]. The powders were suspended in
10 mL of a glucose solution and orally administered to a conscious animal by a syringe (0 min). At 0, 5,
15, 30, 45, 90, 120 and 180 min, blood samples were taken (about 2 mL) through the auricular artery
and put in heparinized tubes. The samples were centrifuged at 2500 g for 5 min and the plasma was
recovered. Acetonitrile was added to the plasma samples (v:v 1:1 ratio) and left for 5 min in order
to precipitate plasma proteins. After centrifugation the supernatant was recovered for the dosage of
resveratrol by HPLC.
Nutrients 2018, 10, 1925 4 of 10
2.7. HPLC Analysis
The measurements were performed by an Agilent HPLC 1200 series equipped with an Agilent
Zorbax SB C18 4.6 × 250 mm 5-µm Agilent P/N 880975-902 column. Elution was carried out under
isocratic conditions using as mobile phase (Water + 0.1% v/v Trifluoroacetic acid)/(Acetonitrile +
0.1% v/v Trifluoroacetic acid) = 65/35, with a flow of 1mL/min and a column temperature of 30 ◦C.
A total of 20 µL of samples were injected, after 0.2 µm Nylon membrane filtration, and the analytes
were detected by VWD Detector, λ = 306 nm. For the quantification of resveratrol a calibration was
performed to detect the polyphenol at a retention time of 5.6 min with a detection limit of 4 ng/mL.
All the plasma concentrations were multiplied by 2 to take into account the dilution in acetonitrile
during sample preparation and by 3.6 to take into account the yield of extraction of resveratrol from
plasma (28%) [19].
2.8. Statistical Analysis
All results are expressed as the mean± SE. Differences between two related parameters were
assessed by Student’s t-test. Differences were considered significant at p < 0.05. The number of animals
used in the current experimental trial is based on the work by Jaisamut et al., 2017 [18].
3. Results
3.1. Microscopic Analysis of Solid Dispersion of Resveratrol on Magnesium Dihydroxide
RSV@MDH powder was dispersed in glycerol and was observed by bright-field microscopy.
The presence of particles with different scattering profiles in a narrow size range of a few micrometers
was observed (Figure 1A). Fluorescence analysis of the samples with DAPI filter showed that about
10–20% of the microparticles emitted fluorescence. These microparticles were defined as type 1
(Figure 1B). The mean size of type 1 microparticles was 1.8 ± 0.1 µm, n = 40 in diameter (given the
non-spherical morphology of the particles, the longest diameter has been taken into account). When the
sample was analyzed with the rhodamine filter, a comparable population of particles was visualized
with a mean size of 2.0 ± 0.2 µm, n = 34 and was named type 2 (Figure 1C). Type 1 microparticles
displayed very scant signals when observed with the rhodamine filter similar to the type 2 particles
with the DAPI filter. Finally, the majority of the microparticles didn’t display any fluorescence in either
filter and were defined as type 3 and had medium size similar to others (Figure 1D).
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Figure 1. Image of Resv@MDH powder dispersed in glycerol under different excitation sources.
(A) Bright-field; (B) DAPI (4′,6-diamidino-2-phenylindole) fluorescence filter; (C) Rhodamine
fluorescence filter; (D) merging of the Bright-field, DAPI and Rhodamine images.
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Thus, the solid dispersion of resveratrol on magnesium dihydroxide was composed by three
distinct populations of microparticles based on the fluorescence profile. When we similarly analyzed
the dry powder without dispersion in glycerol we observed aggregates of size around 5 µm were
present as a possible consequence of the interaction of the three types of microparticles (Figure 2A).
In accordance, that the aggregates are based on different types of microparticles, they displayed
fluorescence signals from every channel. Granulometric and SEM analysis showed two distinct
population sizes, one with size around 1 µm and the second population with size around 6 µm of
diameter (Figure 2B,C).
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3.3. Dissolution of Solid Dispersion of Resveratrol on Magnesium Dihydroxide.
In Figure 4 dissolution profiles of Resv@MDH (red squares) and pure resveratrol (black squares)
are presented (mg/L in function of time). The experimental data was fit with exponential equation
C(t) = Cmax (1 − exp(−t/τ)), where Cmax = maximum solubility value; t = time; τ = time in which
dissolution reaches about 63% of maximum process. The equation represents a form studying the
dissolution profiles according to Weibull’s models [20]. The best data fit is for Cmax: 40.8 and
13 mg/L for Resv@MDH and resveratrol respectively while τ was 0.4 and 2.2 min for Resv@MDH
and resveratrol respectively. These data indicated that Resv@MDH showed a dissolution rate five
times higher than resveratrol (compared to τ) and a maximum solubility three times as big (compared
to Cmax). To assess the importance of particles size in dissolution rate, we compared the solubility
profile of pure micronized resveratrol with similar size particles of Resv@MDH (Figures 3 and 4).
It was possible to see (compare black and green squares in Figure 4A) the reduction of particles size
modified only dissolution kinetic according to the Noise-Witting law, but did not modify the maximal
solubility [21].
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a complex, we verified the interaction between them by performing spectrophotometric profile of
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resveratrol alone or in presence of magnesium ion in acid environment. It is possible to see in Figure 4B,
that the addition of magnesium does not significantly modify the UV absorption spectra, suggesting
that the magnesium does not interact with resveratrol and that the major solubility was dependent on
other factors.
3.4. Pharmacokinetic Profile of Solid Dispersion of Resveratrol on Magnesium Dihydroxide
The rabbit animal model is excellent to perform pharmacokinetic studies [20] and recently
was used to evaluate the bioavailability of a new resveratrol formulation [18]. The mean plasma
concentration of resveratrol following oral administration of 50 mg/kg of Resv@MDH and pure
resveratrol was investigated in the rabbit animal model. Resveratrol plasma concentration versus
time curves from administration is displayed in Figure 5. Pharmacokinetic variables derived from this
pharmacokinetic profile are summarized in Table 2. Resveratrol is virtually absent in animal plasma
prior to oral administration (0 min) but it seemed to be rapidly absorbed with a peak of maximal
concentrations (Cmax) between 15 and 30 min post-dose. The Cmax of resveratrol was 76.3 ng/mL and
101.3 ng/mL for resveratrol and Resv@MDH respectively. At 30 up to 90 min from the administration,
the resveratrol plasma concentration of Resv@MDH treated animals results statistically greater as
compared to resveratrol treated animal, while at 180 min the resveratrol is no longer detectable
in the plasma of both groups of animals. The values of Area Under Curve (AUC) of the plasma
concentration profile until the 3-h time point was 2698 ng min/mL and 8944 ng min/mL or resveratrol
and Resv@MDH respectively. This data demonstrates an enhancement of resveratrols bioaviability by
3.3-fold (ratio of AUCResv@MDH/AUCresveratrol, Table 2).
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Figure 5. Pharmacokinetic profiles of resveratrol after oral administration in rabbits. Groups of 4
animals each were treated with resveratrol (50 mg/Kg of pure resveratrol versus Resv@ DH). Blood
sa ples taken at 0, 5, 15, 30, 45, 90, 120 and 180 in.
Table 2. Pharmacokinetic parameters of oral administration of 50 mg/Kg of resveratrol from pure
resveratrol and from Resv@MDH.
Parameters Resveratrolo50 mg/Kg
Resv@MDH
(Resveratrol 50 mg/Kg) Increase %
AUC (Area Under Curve) 2698 ng min/mL 8944 ng min/mL 330
Time to plasmatic peak 15 min 30 min 200
Peak duration 25 min 105 min 420
Cmax 76.3 ng/mL 101.3 ng/mL 130
4. Discussion
Solid dispersion of resveratrol on magnesium dihydroxide (Resv@MDH) represents a new
formulation that possesses an increased solubility of resveratr l (spring form). Resv@MDH i able to
s lubilize itself faster and in greater amounts with respect to resveratrol, with remarkable advantages
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in biopharmaceutical terms and therefore of bioavailability. From the physical point of view it
is a polydisperse granular material, where the active is supported by inorganic material with a
high safety level (magnesium hydroxide). Furthermore, this improves its performance without
chemically modifying the natural product’s structure. Resv@MDH allows to obtain an apparent
solubility much higher with respect to resveratrol as a consequence of an increased dissolution rate
and of the establishment of over-saturation phenomena due to different energetic states of resveratrol
(Figure 6). This dispersion is formed by three types of microparticles that we define as type 1, 2 and 3.
Based on our results we hypothesized that microparticles type 1 and 3 represent resveratrol and
magnesium dihydroxide crystals, respectively. The unexpected result is the presence of microparticles
type 2 that probably represent the form responsible for enhanced properties of the solid dispersion.
Based on the evidence of change of its fluorescence, we suggest that a fraction of resveratrol forms a
shell around magnesium dihydroxide microparticles. The better solubility of resveratrol displayed by
solid dispersion could be explained by the coexistence of two energetic states of resveratrol related
to the two types of microparticles observed (type 1 and 2, Figure 6). It is possible to exclude the
involvement of free magnesium ions (Mg2+) in improving the solubility of resveratrol since their
absorbance spectrum was not modified by the presence of metals in acidic environment (Figure 4B).
The state of over-saturation could lead to the major absorption (increase of the gradient concentration)
and therefore increased bioavailability [22].
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